SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.96% Stake in Mural Oncology plc

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, revealing a beneficial ownership of 9.96% in Mural Oncology plc as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', beneficially own 1,700,000 ordinary shares of Mural Oncology plc.
• This ownership represents 9.96% of Mural Oncology plc's outstanding ordinary shares.
• The percentage is calculated based on 17,060,310 shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed on November 13, 2024.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over the 1,700,000 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing no direct positive or negative sentiment regarding the company's performance or outlook.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
• Management: Awareness of a significant shareholder, though the filing states no intent to influence control.

Key Dates

Keywords

Mural Oncology plc, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Adviser, Ordinary Shares, Equity Stake, Biotechnology, Oncology